Finch Therapeutics Group, Inc.
FNCHQ evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $16.6M
- Lead Asset:
- cp101 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for FNCHQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FNCHQ
Finch Therapeutics Group, Inc. (FNCHQ) is a microbiome technology company that discontinued its lead Phase 3 clinical trial in January 2023 and now focuses on realizing value from its intellectual property and biorepository assets, with no current expectation of advancing product candidates through clinical trials or generating product revenue [sec_mda · as of 2023-05-10] [sec_mda · as of 2023-11-08].
Key risk: No active clinical development
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$16.6M
Cash Runway
—
Lead Asset
cp101 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2024.
Tracking 2 pipeline candidates · 1 clinical trial for Finch Therapeutics Group, Inc..
Finch Therapeutics Group, Inc. (FNCHQ) is a microbiome technology company that discontinued its lead Phase 3 clinical trial in January 2023 and now focuses on realizing value from its intellectual property and biorepository assets, with no current expectation of advancing product candidates through clinical trials or generating product revenue [sec_mda · as of 2023-05-10] [sec_mda · as of 2023-11-08].
- Cash & equivalents of $16.0M as of 2024-06-30 [sec].
- Total revenue of $0.0M and net loss of -$4.8M for the period ended 2024-06-30 [sec].
- Shareholders' equity of $14.2M as of 2024-06-30 [sec].
- Discontinued its Phase 3 clinical trial of CP101 for recurrent C. difficile infection in January 2023 [sec_mda · as of 2023-05-10].
- Pipeline includes preclinical candidates fin-211 (autism), fin-525 (Crohn's disease), fin-524 (ulcerative colitis), and cp101 (C. difficile) [pipeline].
What works
- The company holds an exclusive, worldwide, royalty-bearing license for patents related to autism spectrum disorder treatments from Arizona State University [pipeline].
- It has developed a significant biorepository of strains and samples that may be valuable for future partnerships [sec_mda · as of 2023-05-10].
- The company has an exclusive license agreement with the University of Minnesota for microbiome product candidates, and investigator-sponsored trials are ongoing [sec_mda · as of 2023-05-10].
What to weigh
- The company discontinued its Phase 3 clinical trial of CP101 in recurrent CDI in January 2023 and does not currently expect to progress any product candidate through clinical trials or commercial approval [sec_mda · as of 2023-05-10] [sec_mda · as of 2023-11-08].
- Finch does not currently expect to generate any revenue from product sales [sec_mda · as of 2023-11-08].
- The company has significantly scaled back expenses by winding down development efforts, liquidating assets, terminating vendor contracts, and reducing headcount [sec_mda · as of 2023-05-10].
- All pipeline candidates are in preclinical stages, with no active clinical development underway [pipeline].
From the filings
Quoted directly from source documents.
Discontinuation of Phase 3 trial and shift in strategy
“In January 2023, we announced the decision to discontinue our Phase 3 clinical trial of CP101 in recurrent CDI and focus on realizing the value of our intellectual property estate and other assets.”
SEC MD&A · May 10, 2023
No expected product revenue or clinical advancement
“We do not currently expect to be able to progress any product candidate through clinical trials or commercial approval, and we do not currently expect to generate any revenue from product sales.”
SEC MD&A · November 8, 2023
Catalyst timeline
- 2026-04-16 · Phase 2 start for MTX-474 in diffuse cutaneous systemic sclerosis — A Phase 2 randomized, double-blind, placebo-controlled study to assess safety and efficacy of MTX-474 in dcSSc; this appears unrelated to Finch's own pipeline and may be an investigator-sponsored or partner trial.
Risks & what to watch (4)›
Key risks
- No active clinical development — Company discontinued its only Phase 3 trial and does not expect to advance any candidate through clinical trials [sec_mda · as of 2023-05-10].
- Zero product revenue expected — Finch does not expect to generate any revenue from product sales [sec_mda · as of 2023-11-08].
- Cash burn with limited runway — Cash of $16.0M as of 2024-06-30 with net loss of -$4.8M in the period; ongoing expenses may deplete cash [sec].
- All pipeline candidates preclinical — All four pipeline candidates are in preclinical phase; none are in active clinical testing [pipeline].
What to watch
- Whether the company can execute strategic partnerships or licensing deals to monetize its intellectual property and biorepository [sec_mda · as of 2023-05-10].
- Progress of investigator-sponsored trials at Brigham and Women's Hospital (CP101 in ulcerative colitis) and University of Minnesota [sec_mda · as of 2023-05-10].
- Cash runway and any further reductions in operating expenses given the net loss and limited revenue [sec].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Finch Therapeutics Group, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Finch Therapeutics Group, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.21 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 22, 2026- % of float
- 2.8%
- Days to cover
- 0.2
- Shares short
- 19,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FNCHQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Finch Therapeutics Group, Inc.?
Finch Therapeutics Group, Inc. (FNCHQ) is a microbiome technology company that discontinued its lead Phase 3 clinical trial in January 2023 and now focuses on realizing value from its intellectual property and biorepository assets, with no current expectation of advancing product candidates through clinical trials or generating product revenue [sec_mda · as of 2023-05-10] [sec_mda · as of 2023-11-08].
What is Finch Therapeutics Group, Inc.'s lead drug candidate?
Finch Therapeutics Group, Inc.'s most advanced tracked candidate is cp101 (Preclinical) for recurrent C. difficile infection.
Who is the CEO of Finch Therapeutics Group, Inc.?
Mr. Matthew P. Blischak J.D. is the chief executive officer of Finch Therapeutics Group, Inc. (FNCHQ).
Where is Finch Therapeutics Group, Inc. headquartered?
Finch Therapeutics Group, Inc. (FNCHQ) is headquartered in Boston, MA, United States.
What therapeutic areas does Finch Therapeutics Group, Inc. focus on?
Finch Therapeutics Group, Inc. develops therapies across Neurology, Immunology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.